1. Home
  2. ALKS
  3. ALKS News

Latest Alkermes plc (ALKS) News on September 5, 2025

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
ALKS

BioPharma Dive

16 days ago

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech

Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
ALKS

TipRanks

3 months ago

Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls

ALKS

MT Newswires

3 months ago

Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says

ALKS

MT Newswires

3 months ago

UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
ALKS

Zacks

3 months ago

Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
ALKS

PR Newswire

3 months ago

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
ALKS

PR Newswire

3 months ago

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 49% Undervaluation?
ALKS

Simply Wall St.

3 months ago

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 49% Undervaluation?

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
ALKS

PR Newswire

3 months ago

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

ALKS

MT Newswires

3 months ago

Needham Initiates Alkermes Public at Buy With $45 Price Target

Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential
ALKS

Insider Monkey

4 months ago

Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

Alkermes First Quarter 2025 Earnings: EPS Beats Expectations
ALKS

Simply Wall St.

4 months ago

Alkermes First Quarter 2025 Earnings: EPS Beats Expectations

Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
ALKS

Zacks

4 months ago

Alkermes' Q1 Earnings and Revenues Fall Short of Estimates

ALKS

MT Newswires

4 months ago

RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating

Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ...
ALKS

GuruFocus.com

4 months ago

Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ...

Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
ALKS

Zacks

4 months ago

Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings

ALKS

MT Newswires

4 months ago

Alkermes Q1 Earnings, Revenue Decline

Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
ALKS

Zacks

4 months ago

Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates

ALKS

Associated Press Finance

4 months ago

Alkermes: Q1 Earnings Snapshot

Alkermes plc Reports First Quarter 2025 Financial Results
ALKS

PR Newswire

4 months ago

Alkermes plc Reports First Quarter 2025 Financial Results

Do Options Traders Know Something About Alkermes Stock We Don't?
ALKS

Zacks

4 months ago

Do Options Traders Know Something About Alkermes Stock We Don't?

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
ALKS

PR Newswire

4 months ago

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ALKS

Zacks

4 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ALKS

MT Newswires

4 months ago

UBS Adjusts Alkermes Public Price Target to $33 From $38, Maintains Neutral Rating

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
ALKS

Zacks

4 months ago

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Alkermes to Report First Quarter Financial Results on May 1, 2025
ALKS

PR Newswire

5 months ago

Alkermes to Report First Quarter Financial Results on May 1, 2025

ALKS

MT Newswires

5 months ago

RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
ALKS

PR Newswire

5 months ago

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia
ALKS

Clinical Trials Arena

5 months ago

Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
ALKS

Zacks

5 months ago

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
ALKS

PR Newswire

5 months ago

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

ALKS

MT Newswires

5 months ago

Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
ALKS

PR Newswire

5 months ago

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
ALKS

Zacks

5 months ago

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?

GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
ALKS

Investor's Business Daily

5 months ago

GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait

Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points
ALKS

Investor's Business Daily

6 months ago

Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?
ALKS

Zacks

6 months ago

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment?
ALKS

Insider Monkey

6 months ago

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment?

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years
ALKS

Simply Wall St.

6 months ago

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years

ALKS

MT Newswires

6 months ago

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says

ALKS

MT Newswires

6 months ago

RBC Initiates Alkermes at Sector Perform With $40 Price Target

ALKS

MT Newswires

6 months ago

UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target

Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025
ALKS

Insider Monkey

6 months ago

Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025

Alkermes to Participate in Upcoming Investor Conferences
ALKS

PR Newswire

6 months ago

Alkermes to Participate in Upcoming Investor Conferences

Alkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
ALKS

Simply Wall St.

7 months ago

Alkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
ALKS

Zacks

7 months ago

Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up

Alkermes Full Year 2024 Earnings: Beats Expectations
ALKS

Simply Wall St.

7 months ago

Alkermes Full Year 2024 Earnings: Beats Expectations

Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone
ALKS

GuruFocus.com

7 months ago

Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone

Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ALKS

Zacks

7 months ago

Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ALKS

MT Newswires

7 months ago

Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday

Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates
ALKS

Zacks

7 months ago

Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates

ALKS

Associated Press Finance

7 months ago

Alkermes: Q4 Earnings Snapshot

ALKS

MT Newswires

7 months ago

Alkermes Q4 Non-GAAP Earnings, Revenue Increase

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
ALKS

PR Newswire

7 months ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

Earnings To Watch: Alkermes PLC (ALKS) Reports Q4 2024 Result
ALKS

GuruFocus.com

7 months ago

Earnings To Watch: Alkermes PLC (ALKS) Reports Q4 2024 Result

ALKS

MT Newswires

7 months ago

Deutsche Bank Initiates Coverage on Alkermes Public With Buy Rating, $40 Price Target

What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings
ALKS

Zacks

7 months ago

What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings

Are orexins the next golden child of neuroscience?
ALKS

Pharma Voice

7 months ago

Are orexins the next golden child of neuroscience?

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
ALKS

PR Newswire

7 months ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

ALKS

MT Newswires

7 months ago

BofA Adjusts Price Target on Alkermes Public to $33 From $31

ALKS

MT Newswires

7 months ago

Alkermes Insider Sold Shares Worth $3,234,382, According to a Recent SEC Filing

Onera’s validation trial of home polysomnography sleep device succeeds
ALKS

Clinical Trials Arena

8 months ago

Onera’s validation trial of home polysomnography sleep device succeeds

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALKS

PR Newswire

8 months ago

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)?
ALKS

Simply Wall St.

8 months ago

Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)?

ALKS

MT Newswires

9 months ago

Alkermes Insider Sold Shares Worth $1,961,406, According to a Recent SEC Filing

Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?
ALKS

Zacks

9 months ago

Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?
ALKS

Zacks

9 months ago

Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?

ALKS

MT Newswires

9 months ago

Alkermes Insider Sold Shares Worth $441,550, According to a Recent SEC Filing

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?
ALKS

Zacks

9 months ago

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?
ALKS

Zacks

9 months ago

Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
ALKS

Zacks

9 months ago

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Axsome Therapeutics eyes approval after Phase III narcolepsy win
ALKS

Clinical Trials Arena

9 months ago

Axsome Therapeutics eyes approval after Phase III narcolepsy win

Alkermes to Participate in Upcoming Investor Conferences
ALKS

PR Newswire

9 months ago

Alkermes to Participate in Upcoming Investor Conferences

Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
ALKS

Zacks

9 months ago

Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

ALKS

MT Newswires

10 months ago

Alkermes Insider Sold Shares Worth $1,774,576, According to a Recent SEC Filing

Alkermes to Participate in Two Upcoming Investor Conferences
ALKS

PR Newswire

10 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
ALKS

PR Newswire

10 months ago

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

ALKS

MT Newswires

10 months ago

Stifel Upgrades Alkermes to Buy From Hold, Adjusts Price Target to $36 From $25

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
ALKS

Zacks

10 months ago

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
ALKS

Simply Wall St.

10 months ago

Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...
ALKS

GuruFocus.com

10 months ago

Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
ALKS

Zacks

10 months ago

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

ALKS

MT Newswires

10 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
ALKS

Zacks

10 months ago

Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates

ALKS

MT Newswires

10 months ago

Alkermes' Q3 Non-GAAP Earnings Rise, Revenue Falls

ALKS

Associated Press Finance

10 months ago

Alkermes: Q3 Earnings Snapshot

Alkermes plc Reports Third Quarter 2024 Financial Results
ALKS

PR Newswire

10 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results

Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect
ALKS

GuruFocus.com

10 months ago

Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Expect

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ALKS

Zacks

10 months ago

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
ALKS

Zacks

10 months ago

Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Alkermes to Report Third Quarter Financial Results on October 24, 2024
ALKS

PR Newswire

a year ago

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits
ALKS

Investor's Business Daily

a year ago

Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits

Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts?
ALKS

Insider Monkey

a year ago

Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts?

Here's Why Alkermes (ALKS) is a Strong Momentum Stock
ALKS

Zacks

a year ago

Here's Why Alkermes (ALKS) is a Strong Momentum Stock

Here's Why Alkermes (ALKS) is a Strong Growth Stock
ALKS

Zacks

a year ago

Here's Why Alkermes (ALKS) is a Strong Growth Stock

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
ALKS

Zacks

a year ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years
ALKS

Simply Wall St.

a year ago

Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
ALKS

PR Newswire

a year ago

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
ALKS

Zacks

a year ago

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
ALKS

PR Newswire

a year ago

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Share on Social Networks: